EUROPEAN UNION INTRA

	I.1. Consignor						I.2. IMSOC ref	erence		I.2.a. I	ocal reference		
	Name						I.3. Central Compete				t Authority		
	Address									cal Competent A			
	Country ISO Code										•	,	
	,												
Ħ	I.5. Consignee						I.6. Operator o	conducting	assembly of	peration	ns independentl	y of an	
of consignment	Name							•					
Ħ	Address						Name						
<u>.</u>	Country			ISO Cod	le		Address Approval Number						
ű							Country	ilibei			ISO Code		
ၓ				country				150 code					
	I.7. Country of orig	gin				ISO Code	I.9. Country of	destinatio	n			ISO Code	
Part I: Description													
ΡĖ	I.8. Region of origi	in				Code	I.10. Region of	destinatio	n			Code	
Ë	I.11. Place of dispa						I.12. Place of d						
esc	Name						Name						
À	Address						Address						
ij	Approval Number	r					Approval Nui	mber					
ar	Country			ISO	Code		Country				ISO Code		
д	-						_						
	I.13. Place of loadi	ng					I.14. Date and	time of de	parture				
	Name												
	Address												
	Approval Number	r											
	Country			ISO	Code								
	I.15. Means of Tra	nsport					I.16. Transpor	ter					
	Mode	Internatio	nal	Identification	nn .		Name						
	Wode	transport		lucililicatio	)1t		Address						
		document					Activity ID Country ISO Code						
							I.17. Accompa	nying docu	ıments				
							Commercial document	f issue					
							reference				71 100 40		
							Country			Place o	of		
	I 10. Transport and						J			13346			
	I.18. Transport co Ambient $\square$	namons			Chilled [	٦			Frozen 🗆				
	Altibletit 🗀				Clineu L	_	1102011						
	I.19. Container No	/ Seal No											
	I.20. Certified as												
	Germinal product	sЦ											
	I.21. For transit th	rough a thi	rd coun	terr									
	Third country	rough a thi	u coun	шу			ISO Code						
	Exit point						BCP code BCP code						
	Entry point												
	I.22. For transit th	rough Mem	ber Sta	te(s)			I.23. For expor	rt					
	Member State				Code		Third country				ISO Code		
							Exit point BCP code  I.25. Journey Log						
	I.26. Total number	r of package	es.		I.27. Tota	l quantity			I.28. Total g	ross we	eight		
	I.30. Description o	f consignm	_			1					I		
	Commodity		Specie	es		Identification	Number	Quantity			Nature of com	modity	
	Identification Ma	Identification Mark Package count Date of collection				Date of collect	tion /		tablishment	/	Туре		
						production		Centre					
			<u> </u>			<u> </u>					<u> </u>		

en 1/7

## **EUROPEAN UNION**

	II. Health information												
	I, the under	, the undersigned official veterinarian, hereby certify that:											
	(1) □ [II.1.	The in vivo	art I have been collected ch	l,									
		II.1.1.	is approve	d and kept i	in a register by the competent authority;								
Part II: Certification		II.1.2.	complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Part 2 of Annex I to Commission Delegated Regulation (EU) 2020/686.]										
	l) of ovine(1)/ caprine(1 stored, and dispatched												
art		II.1.1.	is approve	d and kept i	by the com	petent authority;							
Р		II.1.2.	-	_	_	_	-	onal procedures, faciliti Regulation (EU) 2020/68					
	II.2. The consignment consists of embryos of the ovine or caprine species which comply with the follow conditions as regards classical scrapie:												
	(1)	(1) • either [they were collected from animals which have been kept continuously since birth on a holding or holdings recognised as having a negligible or a controlled risk of classical scrapie in accordance with point 1 of Section A of Chapter A of Annex VIII to Regulation (EC) No 999/2001, except during the period when they were kept at a semen collection centre that complied during that period with the conditions set out in the four indents of point 1.3.(c)(iv) of that Section;]											
	(1)	or	[they were years before years before Section A co period who	collected from the collection of Chapter Act they wer	ction on a holo n with the rec n of Annex VI se kept at a se	s which have been kept continuously for the last three olding or holdings which have complied for the last three equirements laid down in points (a) to (f) of point 1.3. of VIII to Regulation (EC) No 999/2001, except during the semen collection centre that complied during that period four indents of point 1.3.(c)(iv) of that Section;]							
	(1)	o or	[they were collected from animals which have been kept continuously since birth in a Member State or zone of a Member State listed in point 2.3. of Section A of Chapter A of Annex VIII to Regulation (EC) No 999/2001 as having a negligible risk status for classical scrapie;]										
	(1)	$\circ$ or	[they were	collected fr	om ovine an	imals and							
	(1)			$\circ$ either	[are of the	e ARR/ARR prion protein genotype;]							
	(1)			$\circ$ or	[carry at lea	east one ARR allele;] ]							
	II.3.	-	s(1)/ embryo com donor a			are intend	led for artificial rep	roduction and were					
		II.3.1.					the Union, or have into the Union;	entered the Union in					
		II.3.2.						r from establishments u territory, or a zone the					
			II.3.2.1.					sis and B. suis and have a lower health status;	е				
	(1)(3)		□ [II.3.2.2.	caprae and	d M. tubercu	losis) has r		s complex (M. bovis, M. uring the last 42 days p ryos(1);]					

en 2/7

## **EUROPEAN UNION**

÷	-0	ROPEAN UNION			produced (Moder OV/CAP	-OOCIILO-LMD-X-INII(X)
		II. Health information				
Part II: Certification		(1)(4)	□ [II.3.2.2.	(M. bovis, M. caprae an animals kept on the est collection(1)/ production Article 15(3) of Commiss during this period, infe- bovis, M. caprae and M	for infection with Mycobacter d M. tuberculosis) has been cablishments during at least the on(1) of the oocytes(1)/ embryosion Delegated Regulation (Exciton with Mycobacterium tust, tuberculosis) has been reposeneasures were taken in accorted Regulation;]	arried out on the caprine ne 12 month period prior to os(1), as referred to in U) 2020/688, and in case, berculosis complex (M. rted in caprine animals kept
	II: Cer		II.3.2.3.		nosoma evansi) has not been r on(1)/ production(1) of the oo	
1	rart.	(1)	o either	_	ported in the establishments of tion(1) of the oocytes(1)/ emb	
		(1)	o or	collection(1)/ productio	ed in the establishments during on(1) of the oocytes(1)/ embry ments have remained under r	os(1) and following the last
				the infected	d animals have been removed	from the establishment,
				test for surr methods pr (EU) 2020/6	ra (Trypanosoma evansi) with covided for in Part 3 of Annex 88, carried out, with negative tths after the infected animals	I to Delegated Regulation results, on samples taken at
		II.3.3.	clinical sign		narian or a team member and nal diseases on the day of coll	
		II.3.4.		ually identified as provi n Delegated Regulation	ided for in Article 45(2) or (4), (EU) 2019/2035;	or Article 46(1) or (3) of
		II.3.5.	_	d of at least 30 days prio embryos(1) and during	r to the date of first collectior the collection period	n(1)/ production(1) of the
			II.3.5.1.	the occurrence of foot- infection with Rift Valle virus, sheep pox and go	ments not situated in a restric and-mouth disease, infection ey fever virus, infection with oat pox or contagious caprine ant for ovine and caprine ani	with rinderpest virus, peste des petits ruminants pleuropneumonia, or of an
			II.3.5.2.	melitensis and B. suis, i bovis, M. caprae and M evansi), infection with bluetongue virus (serot	stablishment where infection infection with Mycobacteriun infection with Mycobacteriun in tuberculosis), rabies, anthra epizootic haemorrhagic diseatypes 1-24) and, in case of ovidare kept together with ovine t been reported;	n tuberculosis complex (M. ux, surra (Trypanosoma use virus, infection with ne animals and those
			II.3.5.3.	zone due to the occurre	th animals from establishmen ence of diseases referred to in do not meet the conditions ref	point II.3.5.1. or from
			II.3.5.4.	were not used for natu	ral breeding;	
		II.3.6.	comply wit	th the following conditio	ons as regards foot-and-mouth	n disease
			II.3.6.1.	they come from establi		
				situated in reported was period of at	an area where foot-and-mout ithin a 10-km radius centred of t least 30 days immediately pr tes(1)/ embryos(1);	on the establishment for a

## **EUROPEAN UNION**

					produced (Model OV/CAL-OCCITES-IMB-A-INTRA)				
	II. Health info	rmation							
				-	in which foot-and-mouth disease has not been reported during a period of at least 3 months immediately prior to the date of collection of the oocytes(1)/ embryos(1);				
	(1)		o either [II.3.6.2.	they were	e not vaccinated against foot-and-mouth disease;]				
יונטדול	(1)(5)		or [II.3.6.2.	they were vaccinated against foot-and-mouth disease during the period of 12 months prior to the date of collection or production of the embryos and					
rait II. Cei micauoii				II.3.6.2.1.	have not been vaccinated against foot-and-mouth disease within the period of at least 30 days immediately prior to the date of collection of the embryos;				
raiti				II.3.6.2.2.	the semen used for fertilisation was collected from a male donor that complies with the conditions set out in point 1(b) or the semen complies with the conditions set out in point 2 of Chapter I of Part 5 of Annex II to Delegated Regulation (EU) 2020/686;				
				II.3.6.2.3.	prior to freezing, the embryos have been subjected to trypsin washing carried out in accordance with the recommendations of the IETS Manual(6);				
	-			II.3.6.2.4.	the embryos were stored deep frozen for a period of at least 30 days from the date of collection, and during this period the donor animal has not shown clinical signs of foot-and-mouth disease;]				
		II.3.7.		th at least o	one of the following conditions as regards infection with bluetongue :				
	(1)	□ either	[II.3.7.1.	of the oocy infection v bluetongu	been kept for a period of at least 60 days prior to and during collection ytes(1)/ embryos(1) in a Member State or zone thereof free from with bluetongue virus (serotypes 1-24) where no case of infection with the virus (serotypes 1-24) has been confirmed during the last 24 months geted animal population;]				
	(1)	□ and/or	[II.3.7.2.	they have been kept in a seasonally disease-free zone, during the seasonally disease-free period, for a period of at least 60 days prior to and during collection of the oocytes(1)/ embryos(1), in a Member State or zone thereof with an approved eradication programme against infection with bluetongue virus (serotypes 1-24);]					
	(1)	□ and/or	[II.3.7.3.	disease-fro of the ooc competen embryos(1 the Memb	been kept in a seasonally disease-free zone, during the seasonally ee period, for a period of at least 60 days prior to and during collection ytes(1)/ embryos(1), in a Member State or zone thereof where the it authority of the place of origin of the consignment of oocytes(1)/1) has obtained the prior written consent of the competent authority of per State of destination to the conditions for establishment of that y disease-free zone and to accept the consignment of oocytes(1)/1);				
	(1)	□ and/or	[II.3.7.4.	they have been kept in a vector-protected establishment for a period 60 days prior to and during collection of the oocytes(1)/ embryos(1);]					
	(1)	□ and/or	[II.3.7.5.	bluetongu	been subjected to a serological test to detect antibodies to the se virus serogroup 1-24, with negative results, between 28 and 60 days date of each collection of the oocytes(1)/ embryos(1);]				
	(1)	□ and/or	[II.3.7.6.	(serotypes	been subjected to an agent identification test for bluetongue virus s 1-24), with negative results, on blood sample taken on the day of of the oocytes(1)/ embryos(1);]				
		II.3.8.			one of the following conditions as regards infection with epizootic e virus (serotypes 1-7) (EHDV 1-7):				
	(1)	□ either	[II.3.8.1.	they have of the ooc has not be	been kept for a period of at least 60 days prior to and during collection ytes(1)/ embryos(1) in a Member State or zone thereof where EHDV 1-7 een reported for a period of at least the preceding 2 years within a 150 km of the establishment;]				

en 4/7

## **EUROPEAN UNION**

	II. Health infor	rmation										
	(1)	$\square$ and/or	[II.3.8.2.	ent for a period of at least 1)/ embryos(1);]								
uo	(1)	□ and/or	[II.3.8.3.	rhich according to official and have been lowing tests carried out in								
Part II: Certification	(1)		□ either	[II.3.8.3.1.	results, on l	cal test to detect antibodies to EHDV 1-7, with negative a blood sample taken between 28 and 60 days from the date ection of the oocytes(1)/ embryos(1);]]						
art II: Ce	(1)		□ and/or	[II.3.8.3.2. an agent identification test for EHDV 1-7, with negative results, blood sample taken on the day of collection of the oocytes(1)/embryos(1).]								
	II.4.	The oocyte	s(1)/ embryo	os(1) descril	bed in Part I							
		II.4.1.		2(1)/Part 3(					nal health requirements set I to Delegated Regulation			
		II.4.2.	requireme		d for in Artic				lied in accordance with (EU) 2020/686 and that			
		II.4.3.	are transpo	orted in a co	ontainer whi	ch:						
			II.4.3.1.	production	n team under	ered prior to the dispatch by the embryo collection or er responsibility of the team veterinarian, or by an official seal bears the number as indicated in Box I.19;						
			II.4.3.2.	3.2. has been cleaned and either disinfected or sterilised before use, or is single-use container;								
	(1)(7)		□ [II.4.3.3.	has been filled in with the cryogenic agent which not have been previously use								
	(1)(8)	□ [II.4.4.	-		n straws or other packages which are securely and hermetically sealed;							
		II.4.5. are transported in a container where they are separated from each other by physical compartments or by being placed in secondary protective bags.]										
(1)(9) ☐ The in vivo derived embryos(1)/ in vitro produced embryos(1)/ micromanipulated embryos(in Part I were conceived by artificial insemination using semen coming from a semen collect germinal product processing establishment or germinal product storage centre approved for collection, processing and/or storage of semen by the competent authority of a Member State competent authority of a third country, territory or zone thereof listed in Annex X to Committee Implementing Regulation (EU) 2021/404.]									a semen collection centre, tre approved for the a Member State or by the			
	(1)(10) □ [II.6.	The following antibiotic or mixture of antibiotics(11) has been added to the collection, processing, washing or storage media:										

en 5/7

#### **EUROPEAN UNION**

II. Health information

### Notes:

In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Protocol on Ireland / Northern Ireland in conjunction with Annex 2 to that Protocol, references to European Union in this certificate include the United Kingdom in respect of Northern Ireland.

This animal health certificate shall be completed according to the notes for the completion of certificates provided for in Chapter 2 of Annex I to Commission Implementing Regulation (EU) 2020/2235.

# Certification Part I:

Box reference

"Place of dispatch": Indicate the unique approval number and the name and address of the embryo collection or production team of dispatch of the consignment of oocytes or embryos.

I.11:

H

Box reference

"Place of destination": Indicate the address and unique registration or approval number of the

establishment of destination of the consignment of oocytes or embryos.

I.12:

Seal number shall be indicated. Box

reference I.19:

Box Total number of packages shall correspond to the number of containers.

reference

I.26:

Box reference I.30:

"Type": Specify if in vivo derived embryos, in vivo derived oocytes, in vitro produced embryos or micromanipulated embryos.

"Species": Select amongst "Ovis aries" or "Capra hircus" as appropriate.

"Identification number": Indicate the identification number of each donor animal.

"Identification mark": Indicate the mark on the straw or other packages where oocytes or embryos of the consignment are placed.

"Date of collection/production": Indicate the date on which oocytes or embryos of the consignment were collected or produced.

"Approval or registration number of plant/establishment/centre": Indicate the unique approval number of the embryo collection or production team by which the oocytes or embryos were collected or produced.

"Quantity": Indicate the number of straws or other packages with the same mark.

"Test": Indicate for BTV-test: II.3.7.5, and/or II.3.7.6,, and/or for EHD-test: II.3.8,3.1, and/or II.3.8.3.2,, if relevant.

6/7 en

## **EUROPEAN UNION**

E	JROPEAN	UNION	produced (Model 'OV/CAP-OOCYTES-EMB-A-INTRA')							
	II. Health info	ormation								
	Part II:									
	(1)	Delete if not applicable.								
	(2)	Only embryo collection or production teams a register referred to in Article 101(1)(b) of Regu (EU) 2020/686.								
lioin	(3)	Applicable for ovine animals.								
Part II: Certification	(4)	Applicable for caprine animals.								
	(5)	Option available only for the consignment of i	n vivo derived embryos.							
	(6)	Manual of the International Embryo Transfer Society — A procedural guide and general information for the use of embryo transfer technology emphasising sanitary procedures, published by the International Embryo Transfer Society 1 111 North Dunlap Avenue, Savoy, Illinois 61 874 USA (http://www.iets.org/).								
"	(7)	Applicable for frozen oocytes or embryos.								
	(8)									
	(9)	Does not apply to oocytes.								
	(10)	Mandatory attestation in case antibiotics were	e added.							
	(11)	Insert the name(s) of the antibiotic(s) added a	nd its(their) concentration.							
		icer/Official veterinarian	Authority name							
	Name (in ca		Authority name Signature							
	Stamp									

en 7/7